Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial

Table 2

Adverse events and reasons for discontinuation or dose reduction of oral zinc supplementation.

	ZAH group		PPZ group		Total		value
(A) Within 24 weeks
Serum zinc level ≥130 μg/dL	8	(21.6%)	3	(7.9%)	11	(14.7%)	0.093
Serum copper level <30 μg/dL	4	(10.8%)	2	(5.3%)	6	(8.0%)	0.376
Gastrointestinal-related symptoms	23	(62.2%)	16	(42.1%)	39	(52.0%)	0.082
Blood-related symptoms	7	(18.9%)	4	(10.5%)	11	(14.7%)	0.304
Skin-related symptoms	2	(5.4%)	2	(5.3%)	4	(5.3%)	0.978
Other symptoms	1	(2.7%)	2	(5.3%)	3	(4.0%)	0.572
(B) Within 52 weeks
Serum zinc level ≥130 μg/dL	8	(21.6%)	3	(7.9%)	11	(14.7%)	0.093
Serum copper level <30 μg/dL	5	(13.5%)	3	(7.9%)	8	(10.7%)	0.431
Gastrointestinal-related symptoms	23	(62.2%)	16	(42.1%)	39	(52.0%)	0.082
Blood-related symptoms	7	(18.9%)	4	(10.5%)	11	(14.7%)	0.304
Skin-related symptoms	2	(5.4%)	2	(5.3%)	4	(5.3%)	0.978
Other symptoms	2	(5.4%)	2	(5.3%)	4	(5.3%)	0.978

Data are presented as n (%).